Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

Bristol Myers’BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

The global cancer monoclonal antibodies (mAbs) market , valued at $55.6 billion in 2021, is projected to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031. This exponential ...